Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osemitamab - Transcenta Holding

Next Previous
Search
Drug Profile

Osemitamab - Transcenta Holding

Alternative Names: Claudin18.2 monoclonal antibody - Mabspace Biosciences; second generation Claudin 18.2 antibody - Transcenta Holding; TST-001; TST001 - Claudin18.2 monoclonal antibody

Latest Information Update: 24 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transcenta Holding
  • Developer Henan Cancer Hospital; Transcenta Holding
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Gastric cancer; Solid tumours
  • Phase I/II Pancreatic cancer

Most Recent Events

  • 14 Sep 2024 Updated efficacy data from the phase I/II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 29 Aug 2024 Efficacy, adverse events and pharmacokinetics data from the phase I/II trial in Solid tumours released by Transcenta Holding
  • 31 May 2024 Efficacy and adverse events data from a phase I/IIa trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top